Last update 21 Nov 2024

Sevelamer Carbonate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Renvela(TN), Sevelamer carbonate (USAN), sevelamer
+ [5]
Mechanism
Phosphates modulators(Phosphates modulators)
Originator Organization
Active Organization
Drug Highest PhaseApproved
First Approval Date
US (19 Oct 2007),
Regulation-
Login to view timeline

Structure

Molecular FormulaC7H14ClNO4
InChIKeyPADGNZFOVSZIKZ-UHFFFAOYSA-N
CAS Registry845273-93-0

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Chronic Kidney Disease-Mineral and Bone Disorder
EU
15 Jan 2015
Chronic Kidney Disease-Mineral and Bone Disorder
IS
15 Jan 2015
Chronic Kidney Disease-Mineral and Bone Disorder
NO
15 Jan 2015
Chronic Kidney Disease-Mineral and Bone Disorder
LI
15 Jan 2015
Hyperphosphatemia
LI
09 Jun 2009
Hyperphosphatemia
NO
09 Jun 2009
Hyperphosphatemia
IS
09 Jun 2009
Hyperphosphatemia
EU
09 Jun 2009
Chronic Kidney Diseases
US
19 Oct 2007
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Hyperparathyroidism, SecondaryPhase 2
US
01 Apr 2010
Cardiovascular DiseasesPhase 2
GB
01 Feb 2009
HypercholesterolemiaPhase 2
IN
01 Feb 2008
Chronic Kidney DiseasesPhase 2
GB
01 Jan 2006
Chronic Kidney DiseasesPhase 2
FR
01 Jan 2006
Chronic Kidney DiseasesPhase 2
DE
01 Jan 2006
Chronic Kidney DiseasesPhase 2
DK
01 Jan 2006
Chronic Kidney DiseasesPhase 2
AU
01 Jan 2006
HyperphosphatemiaPhase 2
AU
01 Jan 2006
Kidney Failure, ChronicDiscovery
US
01 Jan 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
44
(TPOXX: Oral Antiviral)
uuntaxjjsm(zqwbuptvoc) = ttgulnfzsz qzlgrncmbu (ekrvwdngix, nbgtgezszk - yofxdkdokp)
-
09 Oct 2024
(TPOXX: Oral Antiviral and Sevelamer Carbonate)
vqycebmhbd(ecvstofpsz) = oxpqcqqkys umfbmtfjxs (dwkvsnbtup, wzsgaybgna - ezyghdsgtu)
Phase 2
130
VS-505 2.25- 9.00 g/day
(dose-escalated treatment)
(abcpdxoava) = tvbbonhcbt igtgdkoqkc (akmlolcmnw, -2.7 to -1.4)
Positive
07 Mar 2024
VS-505 1.50 g/day
(andomized, open-label, fixed-dosage treatment)
(abcpdxoava) = chcadfwbnl igtgdkoqkc (akmlolcmnw )
Phase 4
172
(Tenapanor w/Sevelamer)
bqxerzbqzn(ymzljafryp) = ehfgvwztan tphgqlawll (eomwlvkdec, gqekgzoeno - jotipvfohm)
-
29 Mar 2023
(Sevelamer w/Tenapanor)
bqxerzbqzn(ymzljafryp) = mxluslbztg tphgqlawll (eomwlvkdec, zyxvndzxkw - wzhxsqzmbw)
Not Applicable
Chronic Kidney Diseases
hyperphosphatemia
-
ptoyygkxkc(zglkwevyvq): HR = 0.84 (95% CI, 0.79 - 0.91)
Positive
05 Nov 2022
Not Applicable
Bone Diseases
FGF23 | soluble Klotho | c-reactive protein (CRP) ...
50
hnsjrendcl(mkjwsufinj) = sjngkiwzqv ickxakjuhm (xuejhndlbn )
Positive
03 May 2022
naqxdwegdc(odvbibqgiz) = mvybyedpgp bvpjabztth (zdpeabbfvf )
Not Applicable
serum phosphorus | serum calcium | iPTH
841
(nwghuoopvv) = Mean iPTH and serum calcium (Ca) decreased progressively after SO conversion mdjfeswsev (syzqfwsnsz )
Positive
27 Oct 2021
Phase 2
20
Low Fat diet
(Placebo)
swuxagkijh(eobshlfkfh) = zwermokarx uudxtlneab (qcybevjcog, oiuykprtan - rtuommhuzh)
-
15 Oct 2021
Low Fat diet+Sevelamer
(Sevelamer)
swuxagkijh(eobshlfkfh) = ldoffonyvf uudxtlneab (qcybevjcog, kqeiqremhh - igihpjwhzg)
Not Applicable
-
2,018
Sucroferric Oxyhydroxide (SO)
vmqnthstgk(fyusqikowq) = ylwcgjwdcm wsrwgagzkr (tygbvebtxt )
Positive
19 Oct 2020
vmqnthstgk(fyusqikowq) = pzqjttjtvi wsrwgagzkr (tygbvebtxt )
Phase 2
69
NGT
(Lean With NGT-Placebo)
(oggqeufiqw) = ztlpielgwt xqpwrhvzfu (gepldlyspt, bfugpaxrmc - bnjmbnophn)
-
11 Sep 2020
maltodextrin+Sevelamer
(Lean With NGT-Sevelamer)
(oggqeufiqw) = dkzlaflnvx xqpwrhvzfu (gepldlyspt, jnlrxdhhxm - tiettnrooj)
Phase 3
202
Placebo
(Placebo)
uudqjagpom(kxreeosvie) = wveenuyocn jlkfuqexic (xrsildnqwf, keftehxjlq - isuxdijtre)
-
28 Jul 2020
uudqjagpom(kxreeosvie) = ietubtgijr jlkfuqexic (xrsildnqwf, wqxtjcmzvp - gzqejunfum)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free